Latest news with #RefleXionX1
Los Angeles Times
17-04-2025
- Health
- Los Angeles Times
USC Norris Comprehensive Cancer Center Opens Newport Beach Radiation Oncology and Imaging Center
Keck Medicine of USC - Newport Beach Radiation Oncology and Imaging will be the first Orange County facility to offer innovative biology-guided radiation therapy, which interacts with cancer cells to send up-to-the-minute 'signals' identifying where cancer cells are in the body USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, has opened Keck Medicine of USC - Newport Beach Radiation Oncology and Imaging, a state-of-the-art radiation oncology and imaging center, at 4590 MacArthur Blvd. in Newport Beach. The 12,500-square-foot clinical space houses new-to-market imaging and radiation therapy technology in a serene, beach-inspired space designed to help patients feel at ease. 'Our new radiation oncology and imaging center demonstrates our ongoing commitment to providing Orange County with world-class care,' said Rod Hanners, CEO of Keck Medicine. 'We recognize the importance of keeping cancer care close to home and are proud to expand our presence in the community.' The center is equipped with positron emission tomography-computed tomography (PET-CT) imaging and computed tomography (CT) scanners for diagnosis, treatment simulation and monitoring, as well as two state-of-the-art linear accelerators to deliver precision radiation therapy treatment. Keck Medicine of USC - Newport Beach Radiation Oncology and Imaging will be the first clinical site in Orange County, and just the third in California, to offer SCINTIX biology-guided radiation therapy (BgRT) using the new-to-market RefleXion X1 system. Unlike other types of radiation therapy that use static images of a patient's anatomy to map treatment areas, BgRT is the first and only radiation therapy delivery modality that uses a PET radiotracer compound that, once injected into the body, interacts with cancer cells to send up-to-the-minute 'signals' about the location of cancer cells, even as the patient breathes or moves slightly. This helps radiation oncologists track, target and treat cancer cells in real time while minimizing damage to healthy cells, which may alleviate some of the side effects of radiation. BgRT also eliminates the need for placing markers (tiny metal objects positioned inside the patient in or near cancerous tissue to identify where to deliver treatment), as well as enables radiation oncologists to more efficiently treat multiple tumor locations in the same course of therapy. BgRT recently received breakthrough device designation from the U.S. Food and Drug Administration for treating lung tumors and is currently approved for certain patients with lung and bone tumors. Keck Medicine will install a second X1 system with BgRT at a medical facility in Pasadena opening later this year. It will be the first university-based academic institution to offer BgRT at multiple locations, bringing new cancer treatment options to the Los Angeles area, Orange County and surrounding communities. 'This groundbreaking technology enables us to provide the best possible care and offer treatment for patients whose options may be very limited,' said May Lin Tao, MD, radiation oncologist and director of clinical operations, regional radiation oncology clinics, with Keck Medicine. Tao is also clinical associate professor of radiation oncology with the Keck School of Medicine of USC. 'We are thrilled to be the first to offer this revolutionary and potentially life-saving treatment to patients in Orange County.' Keck Medicine of USC - Newport Beach Radiation Oncology and Imaging is less than 15 minutes away from USC Norris' oncology locations in Newport Beach and Irvine, where patients can make appointments with respected medical oncologists who have served Orange County for decades and who treat more medical oncology outpatients in Newport Beach than any other provider. 'This new location expands our spectrum of cancer services in Orange County, ranging from diagnostic imaging to multiple treatment options that optimize outcomes and provide personalized radiation medicine,' said Eric Chang, MD, radiation oncologist with Keck Medicine and chair and professor of radiation oncology with the Keck School. 'The addition of this new location means so much for our patients and their loved ones,' said Louis Vandermolen, MD, medical oncologist with USC Norris Comprehensive Cancer Center, practicing in Newport Beach. 'Our convenient location near our medical oncology offices means that our patients can truly benefit from multidisciplinary, collaborative care from doctors they know and trust.' Information sourced from Keck Medicine of USC. To learn more, contact
Yahoo
10-02-2025
- Business
- Yahoo
RefleXion Expands Access to SCINTIX Therapy with First Freestanding Cancer Center
HAYWARD, Calif., February 10, 2025--(BUSINESS WIRE)--RefleXion Medical, a theranostic oncology company, today announced the scheduled installation of its RefleXion® X1 platform with SCINTIX® biology-guided radiotherapy at Beverly Hills Cancer Center (BHCC), the first freestanding cancer center (FSCC) that has installed the RefleXion X1. "At BHCC, we are committed to advancing cancer care by integrating the latest innovations, ensuring our patients receive the highest quality, cutting-edge treatments," said Arash (Ari) Gabayan, M.D., Chief of Radiation Oncology and Imaging at Beverly Hills Cancer Center. "We are excited to be amongst the first centers in the world to offer our patients this breakthrough technology, which uses the inherent biology of the patient's tumor to precisely direct the radiation beam to its tumor target. "This is a totally new and exciting concept in radiation treatment delivery, and we believe that using the tumor's own biology will transform how patients are treated," Dr. Gabayan continued. The RefleXion X1 machine with SCINTIX therapy is designed to use biology guidance to precisely treat one or more targets within the same treatment session. Early clinical cases have demonstrated that when the tumor moves, SCINTIX therapy autonomously shifts the radiation dose to follow the tumor, thereby safely delivering radiation to the tumor target while sparing radiation exposure to healthy tissue. "We are thrilled to count BHCC and its world-class cancer physicians among our early customers and as our first freestanding cancer center," said Todd Powell, president and CEO of RefleXion. "Their commitment to providing access to cutting-edge cancer treatments like SCINTIX therapy is invaluable." Beginning in 2025, the Centers for Medicare and Medicaid Services (CMS) will expand reimbursement for SCINTIX therapy, introducing new billing codes for FSCCs and professional reimbursement for physicians in both FSCCs and hospital outpatient departments. "We are encouraged that CMS has expanded reimbursement for freestanding cancer centers like BHCC as this supports clinicians who advance clinical adoption of new technologies and treatments," continued Powell. BHCC physicians consulted with Select Healthcare Solutions, a provider of turn-key medical technology solutions to independent physician groups, to integrate SCINTIX therapy into its comprehensive range of cancer treatment options. SCINTIX therapy uses signals emitted from a patient's cancer cells to direct radiation treatment. Patients receive an injection of a small amount of a unique molecule, called a PET tracer, which the cancer cells consume. The X1 detects the signals produced in real time and uses those to determine where to deliver the radiation dose. In contrast, conventional radiotherapy uses static images of anatomy to guide treatment delivery. About Beverly Hills Cancer Center Beverly Hills Cancer Center provides a unique model of exceptional care, integrating advanced clinical trials, cutting-edge diagnostics, and innovative treatments. With highly skilled physicians, a dedicated staff, and a tranquil healing environment, BHCC is recognized as a leading private cancer diagnostic and treatment facility in Southern California and beyond. Learn more at About RefleXion Medical RefleXion Medical develops and commercializes SCINTIX biology-guided radiotherapy, a groundbreaking treatment that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors and is being studied for broader indications. In addition, the company offers the RefleXion® X1 system for conventional radiotherapy for all solid tumors. Learn more at View source version on Contacts Media Contacts: RefleXionAmy Cookacook@ Beverly Hills Cancer CenterSharon NemanSN@
